Skip to Content

Gefitinib Pregnancy and Breastfeeding Warnings

Gefitinib is also known as: Iressa

Gefitinib Pregnancy Warnings

This drug should not be used during pregnancy unless clearly needed as it can cause fetal harm based on its mechanism of action and animal data. AU TGA pregnancy category: C US FDA pregnancy category: Not assigned Comments: Females of reproductive potential should be advised not to get pregnant during therapy; to use effective contraception during treatment and for at least 2 weeks following therapy completion; and of the potential hazard to a fetus/potential risk for pregnancy loss.

Animal studies have revealed evidence of reproductive toxicity, fetotoxicity, and neonatal death at doses below the recommended human dose (RHD), and reduced fertility in females at doses approximately equal to the RHD. There are no controlled data in human pregnancy. AU TGA pregnancy category C: Drugs which, owing to their pharmacological effects, have caused or may be suspected of causing, harmful effects on the human fetus or neonate without causing malformations. These effects may be reversible. Accompanying texts should be consulted for further details. US FDA pregnancy category Not Assigned: The US FDA has amended the pregnancy labeling rule for prescription drug products to require labeling that includes a summary of risk, a discussion of the data supporting that summary, and relevant information to help health care providers make prescribing decisions and counsel women about the use of drugs during pregnancy. Pregnancy categories A, B, C, D and X are being phased out.

See references

Gefitinib Breastfeeding Warnings

Animal studies indicate that this drug and its metabolites are present in the milk of lactating rats at a concentration of 11- to 19-fold higher than in maternal plasma after an oral dose of 5 mg/kg (30 mg/m2, about 0.2 times the recommended human dose on a mg/m2 basis).

-Discontinue breastfeeding during use of this drug. (AU, US) -Use of this drug is contraindicated during breastfeeding. (UK) Excreted into human milk: Unknown Excreted into animal milk: Yes

See references

References for pregnancy information

  1. "Product Information. Iressa (gefitinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.

References for breastfeeding information

  1. "Product Information. Iressa (gefitinib)." Astra-Zeneca Pharmaceuticals, Wilmington, DE.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.